Hi Bravo,Hi Manny,
Thanks for your response!
You say while our reach is broader, in addition "ours is a harder nut to crack" and yet we don't have anywhere near the money in reserve that WBT does?
All I'm suggesting is that the opportunity for shareholders to ask the difficult questions of management presents itself now at the AGM.
These difficult questions need to be respectfully asked and answered IMO.
I agree BODs should be accountable and should be questioned.
The AGM will be interesting.
I mentioned that a comparison between WBT and BRN in 5 years will be interesting. See my earlier post on estimated time frames for AI adoption.
Up until now it's 1%.
2025 to 2030 its estimated at 50% Adoption.
That is an exponential increase.
The next 5 years are make or break for BRN and holders.
The company is aware of this. They are of course extremely confident of the 'make it' side.
Renesas is an extreme example of the Early Adopter lengthy sales cycle.
Licence Dec 2020, chip taped out with a "3rd party" in Dec'22 and still waiting for revenue. But it will come.
I understand its frustrating.
As we move through the cycle the timeframes for adoption will significantly decrease.
Until we see decent sized bookings closed BRN will be classed as a spec stock - no doubt.
That is the punt investors take.
Will BRN 'make it' big in the next 5 years when AI is expected to grow exponentially?
We hold, buy or sell according to our personal view on that question.
For some its avoid. For others its a chance to accumulate early in the cycle.
I am patient, positive and personally bullish but I accept we are all different and have different views. Hence banter.